American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.

  • Take Action to Protect Medical and Public Health Research

    Although Congress reached an agreement to temporarily fund federal agencies and programs – including NIH – through the first several months of fiscal year (FY) 2015, another short-term or full-year funding bill must be passed prior to December 11 to keep the federal government operational and avoid a government shutdown.  Until a final deal is reached, additional cuts in funding for NIH remain a possibility.

  • Urge Congress to Pass the SGR Repeal and Medicare Provider Payment Modernization Act and Provide Stable Medicare Physician Payments

    On February 6, 2014 the leadership of the House Ways and Means and Energy and Commerce Committees and the Senate Finance Committee released a bi-partisan and bicameral bill to repeal the Sustainable Growth Rate (SGR) formula that has driven annual reductions in Medicare payment for physician services. Your advocacy is needed to ensure that the legislation can be considered by the full House of Representatives and Senate before the short-term physician fee update expires on April 1, 2014.

View all action alerts
  • SGR – Where Do We Go from Here?

    As the 113 th Congress winds down, it has become clear that this group of legislators will not be remembered as the one that permanently addressed the issues associated with Medicare physician payment.  Read more to find out what may happen with the SGR in 2015.

  • Friends of Cancer Research and Brookings Institution Address Oncology Drug Development at a Conference on Clinical Cancer Research

    The seventh-annual Conference on Clinical Cancer Research brought together leaders in cancer drug development from federal, health and regulatory agencies, academic research and the private sector for focused discussions on critical issues surrounding the development and regulation of cancer drugs and therapies.

  • ASH Pleased by Newly Released NHLBI Funding Opportunities for Stem Cell-Derived Blood Products for Therapeutic Use

    The National Heart, Lung and Blood Institute (NHLBI) is now accepting applications for  R01  Research Project Grants and  R41 / R43/44  Small Business Technology Transfer Grants that will support research addressing scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics.  The application deadlines for these funding opportunities is February 15 and February 20, 2015, respectively.

  • Laboratory-Developed Tests and the FDA

    The FDA recently indicated that it wishes to begin to provide regulatory oversight of some laboratory-developed tests.  FDA is clear to indicate that it does not wish to include all tests in the regulatory process, and that it wishes to phase in this process over a period of years, starting with those tests that are most high risk. ASH is closely reviewing this proposed guidance in order to prepare comments for submission to the agency.

View all policy news
back to top